Efficacy of Quadruple Regimen with Polaprezinc for Gastric Infection Eradication: Protocol for a Single-centre, Single-blind, Non-inferiority, Randomised Clinical Trial

Overview

Journal BMJ Open

Specialty General Medicine

Date 2020 Nov 18

PMID 33203625

Citations 1

Authors

Dingkun Wu

Zhen Sun

Tingyuan Li

Qinwen Tan

Yue Sun

Tingting Chen

Yujing Liu

Jun Li

Haidong Jiang

Zhiqiang Yuan

Yuqian Zhao

Wen Chen

Affiliations

Soon will be listed here.

Abstract

Introduction: is the most well-known risk factor for gastric cancer. At present, shows varying levels of resistance to different treatments, leading to a lower rate of eradication. The aim of this study is to evaluate the efficacy of polaprezinc-containing quadruple therapy (PQT) for the eradication of infection and, thus, to provide more evidence to inform the clinical treatment of infection in China.

Methods And Analysis: This is a single-centre, single-blind, non-inferiority, randomised controlled trial, enrolling 158 patients with infection. Patients are randomised (1:1) to the two groups for a 14-day therapy. Treatment group: PQT (esomeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, polaprezinc 75 mg) two times per day; control group: bismuth-containing quadruple therapy (esomeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, bismuth potassium citrate 220 mg) two times per day. The primary outcome is the rate of eradication. Secondary outcomes are the incidence of adverse events and the gastrointestinal microbiota distribution. The 16S ribosomal RNA (16S rRNA) next-generation sequencing (NGS) is used to evaluate the effect of two different therapies on the distribution of the gastrointestinal microbiota.

Ethics And Dissemination: This study was approved by the Ethics Committee of Sichuan Cancer Center & Hospital (No. SCCHEC-02-2019-015). Any amendment to the research protocol will be submitted for ethical approval. All participants must provide informed consent. On completion, the results of the study will be published in the appropriate peer-reviewed journal.

Trial Registration Number: ChiCTR1900025800; preresults.

Citing Articles

The Effect of Quadruple Therapy with Polaprezinc or Bismuth on Gut Microbiota after Eradication: A Randomized Controlled Trial.

Wu D, Li X, Li T, Xie W, Liu Y, Tan Q J Clin Med. 2022; 11(23).

PMID: 36498624 PMC: 9739995. DOI: 10.3390/jcm11237050.

References

Atherton J . The pathogenesis of Helicobacter pylori-induced gastro-duodenal diseases. Annu Rev Pathol. 2007; 1:63-96. DOI: 10.1146/annurev.pathol.1.110304.100125. View

Ferreira R, Pereira-Marques J, Pinto-Ribeiro I, Costa J, Carneiro F, Machado J . Gastric microbial community profiling reveals a dysbiotic cancer-associated microbiota. Gut. 2017; 67(2):226-236. PMC: 5868293. DOI: 10.1136/gutjnl-2017-314205. View

Guo Y, Zhang Y, Gerhard M, Gao J, Mejias-Luque R, Zhang L . Effect of on gastrointestinal microbiota: a population-based study in Linqu, a high-risk area of gastric cancer. Gut. 2019; 69(9):1598-1607. PMC: 7456744. DOI: 10.1136/gutjnl-2019-319696. View

Kulich K, Madisch A, Pacini F, Pique J, Regula J, van Rensburg C . Reliability and validity of the Gastrointestinal Symptom Rating Scale (GSRS) and Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaire in dyspepsia: a six-country study. Health Qual Life Outcomes. 2008; 6:12. PMC: 2276197. DOI: 10.1186/1477-7525-6-12. View

Debets-Ossenkopp Y, Pot R, van Westerloo D, Goodwin A, Vandenbroucke-Grauls C, Berg D . Insertion of mini-IS605 and deletion of adjacent sequences in the nitroreductase (rdxA) gene cause metronidazole resistance in Helicobacter pylori NCTC11637. Antimicrob Agents Chemother. 1999; 43(11):2657-62. PMC: 89539. DOI: 10.1128/AAC.43.11.2657. View

Rimbara E, Noguchi N, Kawai T, Sasatsu M . Fluoroquinolone resistance in Helicobacter pylori: role of mutations at position 87 and 91 of GyrA on the level of resistance and identification of a resistance conferring mutation in GyrB. Helicobacter. 2012; 17(1):36-42. DOI: 10.1111/j.1523-5378.2011.00912.x. View

Warren J, Marshall B . Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet. 1983; 1(8336):1273-5. View

Goodwin A, Kersulyte D, Sisson G, Veldhuyzen van Zanten S, Berg D, Hoffman P . Metronidazole resistance in Helicobacter pylori is due to null mutations in a gene (rdxA) that encodes an oxygen-insensitive NADPH nitroreductase. Mol Microbiol. 1998; 28(2):383-93. DOI: 10.1046/j.1365-2958.1998.00806.x. View

Suerbaum S, Michetti P . Helicobacter pylori infection. N Engl J Med. 2002; 347(15):1175-86. DOI: 10.1056/NEJMra020542. View

10.

Malfertheiner P, Bazzoli F, Delchier J, Celinski K, Giguere M, Riviere M . Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet. 2011; 377(9769):905-13. DOI: 10.1016/S0140-6736(11)60020-2. View

11.

Hwang T, Kim N, Kim H, Lee B, Nam R, Park J . Change in antibiotic resistance of Helicobacter pylori strains and the effect of A2143G point mutation of 23S rRNA on the eradication of H. pylori in a single center of Korea. J Clin Gastroenterol. 2010; 44(8):536-43. DOI: 10.1097/MCG.0b013e3181d04592. View

12.

Zamani M, Ebrahimtabar F, Zamani V, Miller W, Alizadeh-Navaei R, Shokri-Shirvani J . Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther. 2018; 47(7):868-876. DOI: 10.1111/apt.14561. View

13.

Bolyen E, Rideout J, Dillon M, Bokulich N, Abnet C, Al-Ghalith G . Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. Nat Biotechnol. 2019; 37(8):852-857. PMC: 7015180. DOI: 10.1038/s41587-019-0209-9. View

14.

Almonacid D, Kraal L, Ossandon F, Budovskaya Y, Cardenas J, Bik E . 16S rRNA gene sequencing and healthy reference ranges for 28 clinically relevant microbial taxa from the human gut microbiome. PLoS One. 2017; 12(5):e0176555. PMC: 5414997. DOI: 10.1371/journal.pone.0176555. View

15.

McColl K . Clinical practice. Helicobacter pylori infection. N Engl J Med. 2010; 362(17):1597-604. DOI: 10.1056/NEJMcp1001110. View

16.

Binh T, Shiota S, Suzuki R, Matsuda M, Trang T, Kwon D . Discovery of novel mutations for clarithromycin resistance in Helicobacter pylori by using next-generation sequencing. J Antimicrob Chemother. 2014; 69(7):1796-803. PMC: 4054984. DOI: 10.1093/jac/dku050. View

17.

Malfertheiner P, Megraud F, OMorain C, Gisbert J, Kuipers E, Axon A . Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2016; 66(1):6-30. DOI: 10.1136/gutjnl-2016-312288. View

18.

Kashimura H, Suzuki K, Hassan M, Ikezawa K, SAWAHATA T, Watanabe T . Polaprezinc, a mucosal protective agent, in combination with lansoprazole, amoxycillin and clarithromycin increases the cure rate of Helicobacter pylori infection. Aliment Pharmacol Ther. 1999; 13(4):483-7. DOI: 10.1046/j.1365-2036.1999.00510.x. View

19.

Hooi J, Lai W, Ng W, Suen M, Underwood F, Tanyingoh D . Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology. 2017; 153(2):420-429. DOI: 10.1053/j.gastro.2017.04.022. View